🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This study is evaluating how ruxolitinib affects premalignant breast cells....
Status
Completed
Location
University of Alabama at Birmingham
Start Date
2018-05-13
Trial ID
NCT02928978
Treatments Being Tested
This open-label, single-arm, Phase II multi-center study enrolled 46 partic...
Status
Completed
Location
Novartis Investigative Site
Start Date
2020-05-20
Trial ID
NCT03774082
Treatments Being Tested
This phase II pilot trial studies how well ruxolitinib phosphate and danazo...
Status
Completed
Location
Mayo Clinic in Arizona
Start Date
2013-04
Trial ID
NCT01732445
Treatments Being Tested
The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib...
Status
No Longer Available
Location
Novartis Investigative Site
Start Date
TBD
Trial ID
NCT05269771
Treatments Being Tested
The presence of IDH mutation is associated with worse survival in patients ...
Status
Completed
Location
Mayo Clinic - Arizona
Start Date
2021-01-14
Trial ID
NCT04281498
Treatments Being Tested
This is a Phase II investigator-Initiated trial of the Investigational Drug...
Status
Completed
Location
Abramson Cancer Center of the University of Pennsylvania
Start Date
2012-04
Trial ID
NCT01594216
Treatments Being Tested
The purpose of the study is to identify the recommended Part 2 dose (R2PD) ...
Status
Active Not Recruiting
Location
City of Hope
Start Date
2022-05-04
Trial ID
NCT05371964
Treatments Being Tested
The purpose of this study is to compare the safety and effects of ruxolitin...
Status
Active Not Recruiting
Location
Memorial Sloan Kettering Cancer Center
Start Date
2019-05-14
Trial ID
NCT03954236
Treatments Being Tested
The prospective multicenter observational cohort study will be offered cons...
Status
Completed
Location
Azienda Ospedaliera Annunziata
Start Date
2021-01-18
Trial ID
NCT06078319
This phase I/II research study is evaluating a combination of drugs called ...
Status
Completed
Location
Dana-Farber Cancer Institute
Start Date
2014-02
Trial ID
NCT02041429
Treatments Being Tested